Stem cell therapy for diabetic foot ulcers shows promise in new study

For individuals with diabetes, the body’s inability to properly control blood sugar levels can lead to a wide range of other problems as time passes. One major issue is a diabetic foot ulcer (DFU), an open sore or wound that is commonly located on the bottom of the foot and caused by poor blood circulation and nerve damage. It occurs in approximately 15% of individuals with diabetes and in severe cases can lead to foot or leg amputation. Unfortunately, there is usually no effective form of treatment for this condition.

However, results from several studies authorized by the Ministry of Health of Nicaragua showed that using a stem cell therapy to treat patients with DFUs was safe and could be beneficial to patients.

The first results in a pilot study after an 18-month period demonstrated safety of the therapy and complete wound healing by nine months. After the six-year mark, five of the initial 10 subjects still demonstrated persistence of clinical benefits. It should be noted that five had passed away due to cardiac and other non-study-related causes.

In another study, the team wanted to determine the safety and efficacy of the stem cell therapy to treat non-healing DFUs greater than 3 centimeters in diameter.

For this clinical trial, 63 people from 35 to 70 years old with Type 2 diabetes and chronic DFU, all of whom were amputation candidates, were treated with a mixture of various types of stem cells obtained from the patient’s own fat tissue. The stem cell therapy was injected directly into the DFU with the hopes of restoring damaged blood vessels and promoting blood circulation and healing.

Patients were seen six months post treatment to evaluate ulcer closure, with 51 patients achieving 100 percent DFU closure and eight having greater than 75 percent. Only three required early amputations and one patient died. At 12 months post treatment, 50 patients had 100 percent DFU healing, while four had greater than 85 percent healing.

In a news release, Dr. Anthony Atala, Director of the Wake Forest Institute for Regenerative Medicine, expressed interest in evaluating this stem cell therapy and results further.

“This work should be reviewed as it demonstrates the possibility of a novel cell injection therapy that can alleviate pain and infection, accelerate wound healing, and possibly avoid amputation.”

The full results of the recent study were published in Stem Cells Translational Medicine.

2 thoughts on “Stem cell therapy for diabetic foot ulcers shows promise in new study

  1. Most diabetes patients have foot ulcers attributed by many factors such as lack of feeling in the foot, poor circulation, foot deformities and irritation. Patients with diabetes for many years tend to develop neuropathy which might affects an individual to reduce or lose the ability of feeling pain in the foot. The high blood glucose is a sole factor to cause the damage of nerve cells and trigger no pain in the foot. It also reduced the body ability to fight off a potency infection and wound healing.

    Recent clinical trial by injecting autologous adipose derived stromal vascular fraction (SVF) cells to treat no healing DFUs. The results showed that majority of patients have ulcer closure, vascular repair and angiogeness after 6-12 months of treatment.

    SVF is a by product of adipose harvesting of excess fatty tissue. This fraction is enriched with adipose derived stem cells which are capable of multilineage differentiation. SVF stem cells have been used in patients with various autoimmune, urological, neurological, pulmonary, ophthalmologist and orthopedic application. Therefore, SVF of adipose tissue is a potent source of preadipocytes mesenchyma stem cells to regenerate T cells, B cells, endothelial progenitor cells and adipose tissue macrophages. Those adipose stem cells are able to secret cytokines, chemokines and growth factors which stimulate wound healing, tissue regeneration and vascularization. Most injected SVF adipose derived stem cells can attach to the lesion and survive for long periods of time. Thus, SVF derived stem cells is an important clinical setting stem cells for multiple clinical applications. However, the amount of growth factors secretion from adipose SVF progenitors is insufficient and take longer period of time for regeneration. The addition of exogenous growth factors may give additional advantage to speed up the process of wound healing and repairing of tissues.

  2. Your research will help thousands of people. How’s your progress with curing or better management of Diabetes? Type 1 in particular. Stem cell and genetic manipulation is the only way forward. More progress and faster results need to be undertaken. 15% of countries budgets are spent due to Diabetes and the various side effects caused by this disease.
    Some of the research and findings resulting from Covid19 pandemic are available and can be used to cure Diabetes.
    Thanks very much.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.